Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) - Overview
Onychomycosis (Tinea Unguium) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Almirall SA
Blueberry Therapeutics Ltd
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
L Pharmaceuticals Ltd
Novabiotics Ltd
Novan Inc
Viamet Pharmaceuticals Inc
Onychomycosis (Tinea Unguium) - Drug Profiles
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-0305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-160 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HXP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ME-1111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
L-3210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NORS-0791 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-3058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-208 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbifine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbifine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbifine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News & Press Releases
Nov 23, 2018: Moberg Pharma: Patent granted for MOB-015 in Chi
Sep 11, 2018: Moberg Pharma has completed enrollment to Phase 3 study for MOB-015 in North America
May 17, 2018: SB208 Increases Daily il Growth Rate over Four Weeks of Treatment
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Nov 20, 2017: Moberg Pharma replaces CRO in Phase 3 studies for MOB-015
Nov 08, 2017: Moberg Pharma provides update on timeline for MOB-015
Jul 27, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting
Jun 21, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th Intertiol Summit on il Diseases
Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
Mar 06, 2017: Viamet Presents Positive Results from Phase 2b Trial of VT-1161 in Onychomycosis at the American Academy of Dermatology Annual Meeting
Mar 01, 2017: Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the American Academy of Dermatology 2017 Annual Meeting
Nov 08, 2016: Hallux Announces Start of Phase 2 Clinical Trial
Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis
Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Cada
Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2019
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H1 2019
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2019
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2019 (Contd..1), H1 2019
Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2019